| scholarly article | Q13442814 |
| P2093 | author name string | Michael Schmidt | |
| Erhard Seifried | |||
| Walid Sireis | |||
| Wolf-Jochen Geilenkeuser | |||
| Kai Hourfar | |||
| P2860 | cites work | Unusual mode of transmission of dengue | Q22255393 |
| Transfusion-associated babesiosis after heart transplant | Q24610281 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| The anaemia of Plasmodium vivax malaria | Q27026970 | ||
| The Chikungunya epidemic in Italy and its repercussion on the blood system | Q27487584 | ||
| Contact irritant responses of Aedes aegypti Using sublethal concentration and focal application of pyrethroid chemicals | Q28487169 | ||
| Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. | Q33337791 | ||
| Review of dengue fever cases in Hong Kong during 1998 to 2005. | Q33379846 | ||
| Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction | Q33396311 | ||
| Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting | Q33464767 | ||
| Infections with flaviviridae. | Q33828383 | ||
| Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany | Q33961680 | ||
| Identity of the causal agents of human babesiosis in Europe | Q33993990 | ||
| NAT and viral safety in blood transfusion. | Q34000458 | ||
| Babesiosis: recent insights into an ancient disease | Q34011362 | ||
| Transfusion-Transmitted Bacterial Infections - Haemovigilance Data of German Blood Establishments (1997-2010). | Q34053233 | ||
| Plasmodium vivax: clinical spectrum, risk factors and pathogenesis | Q34314662 | ||
| Occurrence of natural vertical transmission of dengue-2 and dengue-3 viruses in Aedes aegypti and Aedes albopictus in Fortaleza, Ceará, Brazil. | Q34358412 | ||
| Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine | Q34362872 | ||
| The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. | Q34560849 | ||
| Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial | Q34607042 | ||
| Kinetics of non-structural protein 1, IgM and IgG antibodies in dengue type 1 primary infection | Q34607959 | ||
| Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. | Q34977423 | ||
| Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ | Q35095646 | ||
| Viruses acquired abroad: what does the primary care physician need to know? | Q36365735 | ||
| Malaria and blood transfusion | Q36375445 | ||
| The WHO dengue classification and case definitions: time for a reassessment | Q36531302 | ||
| Malaria parasite diversity and transmission intensity affect development of parasitological immunity in a mathematical model | Q36568243 | ||
| Reduction of Aedes aegypti vector competence for dengue virus under large temperature fluctuations | Q36743836 | ||
| Novel flow cytometry-based screening for bacterial contamination of donor platelet preparations compared with other rapid screening methods. | Q54403699 | ||
| Malaria | Q56763550 | ||
| Persistent parasitemia after acute babesiosis | Q56777602 | ||
| Safety of blood supply for infectious diseases in Latin American countries, 1994-1997 | Q58846348 | ||
| Human Case of Piroplasmosis (Babesiosis) | Q59098590 | ||
| Human existence, disease, and the natural sciences | Q69271046 | ||
| Vertically transmitted babesiosis | Q73583013 | ||
| Malaria | Q82299644 | ||
| [Regulations stability time of platelet concentration for the purpose of reducing life threatening septic transfusion reactions through bacterial contamination: from the 66th meeting of the Working Group on Blood on 9 June 2008 as adopted following | Q83174297 | ||
| How to improve blood safety with respect to bacterial contaminations? | Q83182007 | ||
| [Dengue fever virus (DENV). Position of the Hematologic Working Group of the Federal Ministry of Health] | Q84425825 | ||
| Real-time polymerase chain reaction in transfusion medicine: applications for detection of bacterial contamination in blood products | Q36850529 | ||
| Transfusion transmittable infections - Seroprevalence among blood donors in a tertiary care hospital of Delhi | Q37133674 | ||
| Probable congenital babesiosis in infant, new jersey, USA | Q37203778 | ||
| Two novel real-time reverse transcriptase PCR assays for rapid detection of bacterial contamination in platelet concentrates | Q37575280 | ||
| The blood donor in sub-Saharan Africa: a review | Q37590894 | ||
| Transfusion-transmitted arboviruses | Q37642043 | ||
| Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update | Q37988224 | ||
| Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation | Q38984286 | ||
| Impact of dengue virus infection and its control | Q39092726 | ||
| Clinical and molecular characterization of a near fatal case of human babesiosis in Austria | Q39381306 | ||
| Detection of bacterial contamination in platelet concentrates using flow cytometry and real-time PCR methods. | Q39529670 | ||
| Utility of a commercial nonstructural protein 1 antigen capture kit as a dengue virus diagnostic tool | Q39712131 | ||
| Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. | Q39740523 | ||
| Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma | Q39916621 | ||
| First two autochthonous dengue virus infections in metropolitan France, September 2010. | Q39953972 | ||
| More reasons to dread rain on vacation? Dengue fever in 42 German and United Kingdom Madeira tourists during autumn 2012. | Q40250849 | ||
| The clinical features and outcomes of acute liver failure associated with dengue infection in adults: a case series | Q40255813 | ||
| Detection of mosquito-only flaviviruses in Europe | Q40294518 | ||
| Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico | Q40296125 | ||
| Endemic and opportunistic infections in Brazilian solid organ transplant recipients. | Q40321055 | ||
| Autochthonous dengue fever in Croatia, August-September 2010. | Q40331359 | ||
| Modeling gene sequence changes over time in type 3 dengue viruses from Ecuador | Q40398177 | ||
| Dengue virus in blood donations, Puerto Rico, 2005. | Q40418359 | ||
| Dengue virus infection in late pregnancy and transmission to the infants | Q40420938 | ||
| External quality control assessment in PCR diagnostics of dengue virus infections | Q40533301 | ||
| The effect of short-term, temporary deferral on future blood donation | Q40864172 | ||
| Babesia Microti Infection in Man: Evaluation of an Indirect Immunofluorescent Antibody Test | Q40864440 | ||
| Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates | Q42792674 | ||
| Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood | Q42807082 | ||
| Dengue hemorrhagic fever transmitted by blood transfusion | Q42981989 | ||
| Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture | Q42987407 | ||
| Usefulness of seminested polymerase chain reaction for screening blood donors at risk for malaria in Spain. | Q43192756 | ||
| Cost-effectiveness of implementation methods for ELISA serology testing of Trypanosoma cruzi in California blood banks. | Q43653133 | ||
| Babesia microti seroprevalence in Minnesota blood donors | Q43706156 | ||
| Malaria surveillance--United States, 2011. | Q44139521 | ||
| The risk of malaria transmission by blood transfusion at Cotonou, Benin | Q44145088 | ||
| Transplacental/perinatal babesiosis | Q44263842 | ||
| International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. | Q44626193 | ||
| Sensitivity comparison of two Food and Drug Administration-licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield | Q45363580 | ||
| Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus | Q45395201 | ||
| Impact of donor deferrals for malaria on blood availability in the United States | Q45691095 | ||
| Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units | Q46567111 | ||
| Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential implications for screening algorithms. | Q50494525 | ||
| Transfusion-transmitted Babesia microti identified through hemovigilance. | Q50602371 | ||
| Trypanosoma cruzi parasitemia in US blood donors with serologic evidence of infection. | Q50643851 | ||
| Age-associated decline in resistance to Babesia microti is genetically determined. | Q53896830 | ||
| P433 | issue | 1 | |
| P921 | main subject | emerging pathogen | Q108429945 |
| P304 | page(s) | 10-17 | |
| P577 | publication date | 2013-12-27 | |
| P1433 | published in | Transfusion Medicine and Hemotherapy | Q15758504 |
| P1476 | title | Emerging Pathogens - How Safe is Blood? | |
| P478 | volume | 41 |
| Q40873084 | Babesia divergens builds a complex population structure composed of specific ratios of infected cells to ensure a prompt response to changing environmental conditions |
| Q40754414 | Detection of Plasmodium falciparum and Plasmodium vivax subclinical infection in non-endemic region: implications for blood transfusion and malaria epidemiology |
| Q35808368 | First Documented Transmission of Trypanosoma cruzi Infection through Blood Transfusion in a Child with Sickle-Cell Disease in Belgium |
| Q41478316 | Identification of the Babesia-responsive leucine-rich repeat domain-containing protein from the hard tick Haemaphysalis longicornis |
| Q26775408 | Improving platelet transfusion safety: biomedical and technical considerations |
| Q26865004 | Legal and ethical issues in safe blood transfusion |
| Q33420599 | Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions |
| Q33841435 | Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? |
| Q58392675 | Patient blood management: A role for pharmacists |
| Q37045828 | Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland |
| Q40058562 | Seroprevalence of Asymptomatic Dengue Virus Infection and Its Antibodies Among Healthy/Eligible Saudi Blood Donors: Findings From Holy Makkah City |
| Q28830861 | The European Hematology Association Roadmap for European Hematology Research: a consensus document |
| Q43198105 | Transfusion safety from the viewpoint of a musical quintet |
Search more.